Medicine Manufacturer Vietnam | Vinphaco at National Respiratory Medicine Conference 2026 — Can Tho

Medicine Manufacturer Vietnam 2026 — Vinphaco’s Clinical Engagement Reaches Vietnam’s Most Underserved Healthcare Region 

For international partners evaluating a medicine manufacturer Vietnam relationship, one of the most meaningful signals of a pharmaceutical company’s market integration is not its product list — it is the depth and consistency of its presence within the clinical ecosystem where those products are used. On June 20, 2026, Vinphaco attended the national conference «Respiratory Medicine: From Clinical Practice Foundations to Advanced Updates» in Can Tho — a gathering of nearly 300 clinicians from across Vietnam, with particularly strong representation from the Mekong Delta region, one of the country’s most clinically underserved areas. For further context on Vinphaco’s Vietnamese operations, visit vinphaco.vn. 

 

1.Vietnam’s Annual Respiratory Medicine Conference — Scale and Significance 

The Respiratory Medicine conference is one of Vietnam’s most established annual scientific forums in its specialty — bringing together leading pulmonologists, internal medicine specialists, and frontline clinicians from hospital systems across the country to exchange clinical experience and update practice standards. The 2026 Can Tho edition focused on two complementary objectives: standardising clinical practice across hospital tiers, and updating clinicians on the latest advances in respiratory disease diagnosis and treatment with direct applicability to Vietnamese patient populations. 

Nearly 300 attending clinicians — spanning pulmonology, internal medicine, emergency, and critical care — represent a cross-section of the medical professionals who prescribe, administer, and evaluate the performance of respiratory medicines in real-world Vietnamese clinical settings. For a medicine manufacturer Vietnam whose active ingredient portfolio includes products used in respiratory and critical care contexts, this is precisely the clinical environment that matters most. 

2.Mekong Delta — A Region With Distinct Respiratory Disease Burden 

The Mekong Delta region presents a respiratory disease profile that is both clinically significant and frequently under-resourced relative to its burden. Tropical humidity, seasonal agricultural burning, and high smoking prevalence create above-average rates of COPD, chronic bronchitis, and respiratory infections across the region’s population of over 17 million. Specialist pulmonologist density in the Mekong Delta remains lower than in major urban centres — making annual events like the Can Tho conference a critical professional development resource for clinicians managing complex respiratory caseloads with limited specialist peer support. 

Vinphaco’s participation in this event — including sponsoring attendance for 10 medical delegates — reflects an understanding of where clinical need is greatest and where pharmaceutical partnership support makes the most meaningful difference. This is not generic conference sponsorship. It is targeted clinical engagement in the specific geographic and specialty contexts most relevant to our product portfolio. 

3.Vinphaco’s Clinical Engagement Strategy — Consistent, National, and Accumulating 

The Can Tho respiratory conference represents the latest in Vinphaco’s sustained 2026 clinical engagement program. Earlier in June, Vinphaco hosted the Vinphaco Speaker Tour 2026 at Bac Ninh General Hospital No. 2 — bringing three National Lung Hospital specialists to nearly 100 healthcare professionals in northern Vietnam. The Can Tho conference extends that engagement to the south, completing a national clinical presence that spans Vietnam’s major medical regions. 

For international pharmaceutical buyers and contract manufacturing partners, this pattern of clinical engagement matters for supplier evaluation in two specific ways. First, it confirms that Vinphaco’s products are actively integrated into Vietnamese clinical practice at the specialist level — not simply listed in a catalogue. Second, it demonstrates that Vinphaco’s medical affairs capability is sophisticated and sustained enough to support multi-region, multi-specialty clinical education — a level of healthcare system integration that reflects genuine market depth, not surface-level marketing activity. 

4.Respiratory Medicine — A Priority Disease Area Across Vinphaco’s Export Markets 

The clinical focus of the Can Tho conference — respiratory disease management, from foundational practice to advanced updates — reflects a disease burden that extends well beyond Vietnam’s borders. Across Vinphaco’s 24-country export network spanning Asia, Africa, and Oceania, respiratory diseases consistently rank among the leading causes of hospitalisation and mortality. 

Tuberculosis remains endemic across significant portions of Vinphaco’s Asian and African export markets. COPD prevalence is rising across middle-income countries in Southeast and Central Asia as smoking rates and air quality deterioration compound. Respiratory infections — bacterial and viral — continue to drive acute care demand across Sub-Saharan Africa and Pacific island markets where healthcare infrastructure is still developing. Vinphaco’s domestic clinical engagement in respiratory medicine is therefore directly relevant to the international markets we serve — informing our understanding of therapeutic standards, treatment protocols, and the clinical requirements that our active ingredient portfolio must meet. 

5.What Clinical Partnership Depth Signals to International Buyers 

A medicine manufacturer Vietnam that invests consistently in clinical education — bringing specialists to provincial clinicians, sponsoring national conference attendance, and maintaining presence across the full geographic span of the domestic healthcare system — is one whose product quality claims are grounded in real-world clinical accountability. 

Medicines that are presented and discussed at national specialist conferences are medicines whose performance is subject to the scrutiny of hundreds of experienced clinicians. A manufacturer that welcomes that scrutiny — by actively facilitating the clinical dialogue in which its products are evaluated — is one that is confident in what it makes. 

For international distributors, importers, and pharmaceutical contract manufacturing buyers, this clinical accountability culture is part of what makes Vinphaco a partner worth a long-term relationship — not simply a supplier worth a purchase order. 

To discuss pharmaceutical partnership, contract manufacturing, or export distribution arrangements: vinphaco.net/contact | vinphaco.vn